Protara Therapeutics gains on mid-stage data on bladder cancer therapy

Protara Therapeutics

05/12/2024 12:37

** Shares of biotech firm Protara Therapeutics  TARA.O  rise
50% to $5.32 premarket 
    ** Co says its experimental cell therapy to treat a type of
bladder cancer helped remove all signs of cancer in 72% of
patients at six months of treatment in an open-label mid-stage
study
    ** The therapy, TARA-002, showed a favorable safety and
tolerability profile and no patients discontinued due to
side-effects - TARA
    ** TARA-002 is being developed to treat high-risk non-muscle
invasive bladder cancer (NMIBC) 
    ** Bladder cancer is the sixth most common cancer in the
United States, with NMIBC representing ~80% of bladder cancer
diagnoses -TARA
    ** Up to last close, stock up ~89% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))